What is Aetion?
Aetion, Inc. operates at the intersection of epidemiology and advanced data science, providing a robust platform that transforms real-world data into scientifically validated evidence. The company serves life sciences organizations by offering rapid, transparent, and rigorous analysis of treatment outcomes, costs, and clinical efficacy. By bridging the gap between raw data and regulatory-grade insights, Aetion enables stakeholders to make informed decisions regarding drug development, payment innovation, and market access. Its position as a leader in the RWE landscape is supported by a deep bench of expertise in health outcomes research, allowing it to address the most complex challenges within the global healthcare ecosystem.
How much funding has Aetion raised?
Aetion has raised a total of $203.2M across 3 funding rounds:
Series A
$11.2M
Series B
$82M
Series C
$110M
Series A (2017): $11.2M with participation from Flare Capital Partners and Lakestar
Series B (2020): $82M led by Oxeon, Amgen Business Development, Flare Capital Partners, JJDC, Greenspring Associates, Lakestar, and EDBI
Series C (2021): $110M supported by Foresite Capital, Warburg Pincus, New Enterprise Associates, Flare Capital Partners, and B Capital Group
Key Investors in Aetion
Flare Capital Partners
Flare Capital Partners is a leading investor focused on healthcare technology, collaborating with entrepreneurs to enhance healthcare outcomes and reduce costs.
Lakestar
Lakestar is a venture capital firm dedicated to partnering with visionary tech entrepreneurs to fund innovative ideas and companies that shape modern life.
Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm renowned for its expertise in growth investing and building long-term, sustainable success.
What's next for Aetion?
Looking ahead, Aetion is well-positioned to capitalize on the increasing demand for data-driven decision-making in the pharmaceutical and healthcare industries. The recent influx of capital is expected to accelerate the expansion of its evidence platform, potentially deepening its integration into global regulatory workflows and commercialization pathways. As the industry shifts toward value-based care, Aetion's ability to provide rapid, high-fidelity evidence will likely remain a core competitive advantage. The company is expected to focus on scaling its operational capabilities and enhancing its analytical tools to meet the evolving needs of its enterprise-level clientele, further cementing its role as an essential infrastructure provider in the digital health transformation.
See full Aetion company page
